There are many different types of XRF analyzers, all of which can be acquired in a wide variety of configurations, providing customers with a vast ran
We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
October 30, 2020 07:28 ET | Source: Research and Markets Research and Markets
Dublin, Oct. 30, 2020 (GLOBE NEWSWIRE) -- The "Blood Collec
Supply chain woes, including backed-up containers at the Port of Los Angeles, are one reason for scarce medical devices.
When Henry Genung was 4 months old, doctors cut a hole in his windpipe and inserted a tube to help him breathe. Born with a rare genetic mutation that blocked his uppe
The vacuum blood collection tube market size to reach $4,507.70 million by 2028 from $2,598.78 million in 2021 to grow at a CAGR of 8.2% from 2021 to 2028; while in 2021, serum separating tubes held largest market share and EDTA tubes segment expected to grow at the fastest rate in the coming
Before the business of 2018 consumes all your brain power, take some time to reflect on the major findings of the last year. We have compiled some of our favorite stories from 2017 into seven major themes, ranging from therapeutics in clinical trials to fundamental molecular biology. Be forewa
Recommendations aim to reduce clinical impact of shortages and protect patient access to coagulation testing.
WASHINGTON--(BUSINESS WIRE )--With a national shortage of certain test tubes to collect blood for coagulation testing, the College of American Pathologists (CAP) published rec
Exclusive analysis of biotech, pharma, and the life sciences
I n May 2010, Corrie Painter received shocking news: She had angiosarcoma, an extremely rare cancer that forms in blood vessels and lymph vessels. Painter, who by that point had a Ph.D. in biochemistry from the University of M
Tasso cofounders Erwin Berthier and Ben Casavant at the company's Seattle factory.
What if you could draw blood at home rather than having it done at the doctor’s office? That’s the premise of Tasso, a Seattle-based startup that’s riding the wave of virtual healthcare.
Recent studies are focused on the development of natural therapeutic alternatives, which are easy to prepare, non-toxic or biocompatible to living tissues and economically inexpensive. The goal is the local release of growth factors, in turn accelerating hard- and soft-tissue healing.